ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1017

BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1

Arjan van Caam, Esmeralda Blaney Davidson, Ellen W. van Geffen, Wim B. van den Berg and Peter M. van der Kraan, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cell Signaling, chondrocytes and transforming growth factor, OA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Osteoarthritis is characterized by degradation of articular cartilage. TGFβ-superfamily signaling via Smad phosphorylation (pSmad) plays a crucial role in cartilage maintenance. Two distinct pSmad pathways exist: pSmad1/5/8 and pSmad2/3. pSmad2/3 induces matrix formation and protects cartilage against deleterious processes like chondrocyte hypertrophy and IL1-signalling. In contrast, pSmad1/5/8 is linked to chondrocyte hypertrophy and expression of the main cartilage degrading enzyme: MMP13. Recently a very potent pSmad1/5/8 inducing ligand has been identified: BMP9. BMP9 is produced by the liver and circulates in high levels. Over 60% of all BMP activity in serum can be attributed to BMP9, showing the abundance of this BMP. In this study we investigated the effect of this potent pSmad1/5/8 inducing ligand, BMP9, on chondrocyte phenotype. Furthermore, because of pSmad2/3’s importance in chondrocyte homeostasis, we studied the interaction between BMP9-signaling and TGFβ1-induced pSmad2/3 signaling.

Methods

In this study, primary bovine chondrocytes were used. BMP9-induced Smad phosphorylation was detected after 1 h and 2 h using Western Blot . Subsequently, BMP9-induced gene expression was measured up to 24 h using real time qPCR. Biological activity of pSmad2/3 was measured using the (CAGA)12-luc reporter assay, which produces luciferase in response to pSmad3. Cellular hypertrophy was investigated by culturing chondrocytes 1 week in the presence of growth factors and analyzing gene expression of hypertrophy markers.

Results

In primary bovine chondrocytes, BMP9 stimulation in doses upwards of 50 pg/ml induced pSmad1/5/8, which was reflected in expression of the Smad1/5/8 response gene bId1. Remarkably, BMP9 doses of 1 ng/ml and higher also induced pSmad2, but, expression of the pSmad3 response gene bSerpine1 was not induced. Co-stimulation of chondrocytes with BMP9 and a low dose TGFβ1 (0.1 ng/ml) reduced BMP9-induced pSmad1/5/8 and, surprisingly, enhanced TGFβ1-induced pSmad2. After 24 hours, this interaction was reflected in mRNA levels, as co-stimulation increased expression of the pSmad2/3 responsive genes: bSerpine1, bTgfb1 and bSmad7 and decreased expression of bId1. Furthermore, BMP9 also synergistically enhanced biological activity of TGFβ1 in the CAGA12Luc reporter assay. The uniqueness of this synergy between BMP9 and TGFβ1 was illustrated by co-stimulation of chondrocytes with TGFβ1 and two other BMPs important in chondrocyte biology: BMP2 and BMP7, which showed that both these BMPs do not synergize with TGFβ1 on Smad2/3p. As a more long term effect, BMP9 induced chondrocyte hypertrophy after one week of stimulation, as indicated by upregulation of Alkaline phosphatase and Col10a1, however addition of 0.1 ng/ml of TGFβ1 inhibited this BMP9-induced hypertrophy.

Conclusion

Our results show that BMP9 potently induces pSmad1/5/8 and its downstream gene expression in chondrocytes. In long term culture this results in induction of chondrocyte hypertrophy. However TGFβ1 can potently inhibit this hypertrophy.  Possibly, this runs via the observed but yet unexplained pSmad2/3 enhancing interaction between both growth factors, which is unique for BMP9 compared to BMP2 or BMP7.


Disclosure:

A. van Caam,
None;

E. Blaney Davidson,
None;

E. W. van Geffen,
None;

W. B. van den Berg,
None;

P. M. van der Kraan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bmp9-induced-psmad158-signaling-and-chondrocyte-hypertrophy-are-effectively-inhibited-by-tgf%ce%b21/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology